Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

QTTB Stock Performance Following the news, shares of Q32 Bio hit an all-time low of $5.80. The latest announcement did not impress investors, who raised concerns about the drug’s efficacy. Wall ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory ...

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports.

Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA ...

In a turbulent market environment, QTTB stock has reached a 52-week low, trading at $2.44, marking a stark contrast to its 52-week ...

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...